| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 02/05/2003 | CN1100778C Pyrrolopyriidines and processes for preapring thereof |
| 02/05/2003 | CN1100777C N-heterocyclic derivatives as NOS inhibitor |
| 02/05/2003 | CN1100774C Compounds having both potent calcium antagonist and antioxidant activity and use thereof as cytoprotective agents |
| 02/05/2003 | CN1100773C Benzofran carboxamides and sulphonamides |
| 02/05/2003 | CN1100748C Inhibition of matrix metalloproteases by 2-substituted-4-(4-substituted phenyl)-4-oxobutyric acids |
| 02/05/2003 | CN1100564C Medicine for treating HIV infection, its composition and its use |
| 02/05/2003 | CN1100559C Health-care composition and its preparing method |
| 02/05/2003 | CN1100540C Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
| 02/05/2003 | CN1100539C Antifungal coposition |
| 02/05/2003 | CN1100535C Pharmaceutical agents for treatment of emesis |
| 02/05/2003 | CN1100533C Melatonin derivatives for usein terating desynchronization disorders |
| 02/04/2003 | US6515173 Inhibitors of the ICE/ced-3 family of cysteine proteases |
| 02/04/2003 | US6515135 Aminoaryl oxazolidinone N-oxides |
| 02/04/2003 | US6515133 Certain diaryl imidazoles act as partial agonists or antagonists for NPY receptors, in particular NPY 5 receptors. They are of use, for example in treating loss of appetite. Such compounds bear aryl groups in the 2 position. |
| 02/04/2003 | US6515124 Dehydroamino acids |
| 02/04/2003 | US6515105 Vascular Endothelial Growth Factor binding to extracellular domain of NP-1 (Neuropilin-1); bioactive complexes; mediate useful cell responses or antagonize undesired biological activities; angiogenesis; cell differentiation |
| 02/04/2003 | US6515027 Substituted benzanilides as CCR5 receptors ligands, antiinflammatory agents and antiviral agents |
| 02/04/2003 | US6515020 Combination of carnitines and resveratrol for prevention or treatment of cerebral and ageing disorders |
| 02/04/2003 | US6515005 Substituted azole derivatives as inhibitors of corticotropin releasing factor |
| 02/04/2003 | US6515004 Useful in the treatment of Alzheimer's disease, chemotherapy-induced alopecia, and cardiovascular disease |
| 02/04/2003 | US6514999 A substance which increases Dopamine concentration in the synaptic cleft of the neurons of the brain, in combination with an effective amount of a local anesthetic of the anilide group or derivatives thereof |
| 02/04/2003 | US6514997 Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis |
| 02/04/2003 | US6514992 Caspases and apoptosis |
| 02/04/2003 | US6514989 Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives |
| 02/04/2003 | US6514985 Induce the biosynthesis of cytokines such as interferon and tumor necrosis factor; exhibit antiviral and antitumor properties |
| 02/04/2003 | US6514984 Human non-pancreatic secretory phospholipase A2 inhibitors |
| 02/04/2003 | US6514983 Inhibitors of the nucleic enzyme poly(adenosine 5'-diphospho-ribose)polymerase |
| 02/04/2003 | US6514977 For treating p38 kinase mediated disorders |
| 02/04/2003 | US6514976 Arylpiperazines having activity at the serotonin 1A receptor |
| 02/04/2003 | US6514974 Pyrido-, pyrimido-, pyridazo- and pyrazo- pyridazines having angiogenesis inhibiting activity |
| 02/04/2003 | US6514970 Urotensin-II receptor antagonists |
| 02/04/2003 | US6514968 Treating a disease or condition in a mammal wherein the 5-HT receptor is implicated and modulation of 5-HT function is desired comprising |
| 02/04/2003 | US6514964 Treating diseases, conditions or disorders mediated by integrin receptors, such as vitronectin and fibronectin receptors |
| 02/04/2003 | US6514961 Such as anxiety and all forms of epilepsy, particularly in humans |
| 02/04/2003 | US6514956 For treating diseases associated with progestogen dependence and for fertility control, abortion or contraception and for anticancer use |
| 02/04/2003 | US6514952 For the treatment and prophylaxis of diseases which are caused by an undesired extent of leucocyte adhesion and/or leucocyte migration such as rheumatoid arthritis or allergic disorders |
| 02/04/2003 | US6514761 Methods of using BCL-2 for the therapeutic treatment and prevention of diseases |
| 02/04/2003 | US6514745 Oncoprotein protein kinase |
| 02/04/2003 | US6514738 Given amino acid sequence; microtubular depolymerization activity in presence of ATP; can be used in diagnosis and treatment of cancer, neurological and vesicular transport disorders. |
| 02/04/2003 | US6514729 Recombinant interferon-beta muteins |
| 02/04/2003 | US6514724 Isolated polynucleotide encoding a polypeptide which has high binding affinity. |
| 02/04/2003 | US6514711 Which forms a reconstructed epidermis, used to test various factors on human skin equivalent, such as drugs, cosmetics, surfactants and detergents |
| 02/04/2003 | US6514696 Detection thereof; Using polynucleotide that hybridizes to given nucleotide sequence; Cancer |
| 02/04/2003 | US6514686 Alzheimer's disease |
| 02/04/2003 | US6514527 Compositions comprising a mixture of bioflavonols |
| 02/04/2003 | US6514520 Containing about 0.05 to about 5 mg/mL of an aminopolycarboxylic acid, including salts such as disodium EDTA; especially the antihistamines loratadine, descarboethoxyloratadine, and azatadine |
| 02/04/2003 | US6514516 Local anesthetic and a biocompatible controlled release material consisting of polyanhydrides, copolymers of lactic acid and glycolic acid, poly(lactic) acid, poly(glycolic) acid, polyesters, polyorthoesters, proteins, polysaccharides |
| 02/04/2003 | US6514513 Costimulatory blockade and mixed chimerism in transplantation |
| 02/04/2003 | US6514491 Hydrolytically degradable carbamate derivatives of poly(ethylene glycol) |
| 02/04/2003 | CA2290766C Method of treating nitrate-induced tolerance |
| 02/04/2003 | CA2272927C Dimesylate salts of neuropeptide y ligands |
| 02/04/2003 | CA2271478C Tissue specific expression of retinoblastoma protein |
| 02/04/2003 | CA2253490C Use of il-12 and ifn-.alpha. for the treatment of infectious diseases |
| 02/04/2003 | CA2171953C Modified truncated complement system regulators |
| 02/04/2003 | CA2063810C Production of vascular endothelial cell growth factor |
| 02/04/2003 | CA2060325C Polypeptides with a dopaminergic receptor activity; nucleic acids coding for these polypeptides and use of the latter for screening active substances on said polypeptides |
| 02/03/2003 | WO2002016548A2 Novel g protein-coupled receptor |
| 02/03/2003 | CA2418130A1 Novel g protein-coupled receptor |
| 02/01/2003 | CA2395006A1 Dual inhibitors of wax ester and cholesteryl ester synthesis for inhibiting sebum production |
| 01/31/2003 | WO2002007761A1 Inhibiting hepatitis c virus processing and replication |
| 01/31/2003 | CA2416603A1 Inhibiting hepatitis c virus processing and replication |
| 01/30/2003 | WO2003008644A1 Method of screening abc protein promoter/inhibitor |
| 01/30/2003 | WO2003008643A2 Methods and polynukleotides for assaying the activity of a dna modifying enzyme |
| 01/30/2003 | WO2003008635A2 η-SECRETASE IN VITRO SCREENING ASSAY |
| 01/30/2003 | WO2003008630A2 Methods of profiling gene expression, protein or metabolite levels |
| 01/30/2003 | WO2003008590A1 Human mitochondrial gpat |
| 01/30/2003 | WO2003008581A1 p53-DEPENDENT APOPTOSIS-INDUCING PROTEIN AND METHOD OF SCREENING APOPTOSIS REGULATOR |
| 01/30/2003 | WO2003008578A2 Reagents and methods for identifying gene targets for treating cancer |
| 01/30/2003 | WO2003008577A1 Novel transformed cells, method of screening antiaging agent and antiaging agents |
| 01/30/2003 | WO2003008574A1 Mutations in ion channels |
| 01/30/2003 | WO2003008452A2 Bispecific monoclonal antibodies to il-12 and il-18 receptors |
| 01/30/2003 | WO2003008449A1 Ntb-a, a surface molecule involved in natural killer cells activity |
| 01/30/2003 | WO2003008446A1 Polypeptides relating to signal transfer of advanced glycation end product receptor |
| 01/30/2003 | WO2003008444A2 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 01/30/2003 | WO2003008443A2 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 01/30/2003 | WO2003008430A2 Porphyrin derivatives for photodynamic therapy |
| 01/30/2003 | WO2003008422A1 Chemical compounds |
| 01/30/2003 | WO2003008419A1 2-(AMINOMETHYL)-TETRAHYDRO-9-OXA-1,3-DIAZA-CYCLOPENTA[a]NAPHTHALENYL DERIVATIVES WITH ANTIPSYCHOTIC ACTIVITY |
| 01/30/2003 | WO2003008418A1 Imidazo-triazine derivatives as ligands for gaba receptors |
| 01/30/2003 | WO2003008414A1 Chemical compounds |
| 01/30/2003 | WO2003008413A1 Imidazopyridinones as p38 map kinase inhibitors |
| 01/30/2003 | WO2003008412A2 Hetero-bicyclic crf antagonists |
| 01/30/2003 | WO2003008411A1 Substituted piperazine compounds and their use as fatty acid oxidation inhibitors |
| 01/30/2003 | WO2003008409A1 Quinoline derivatives and their use as tyrosine kinase inhibitors |
| 01/30/2003 | WO2003008407A2 Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use |
| 01/30/2003 | WO2003008399A1 Synthesis of udp-glucose: n-acylsphingosine glucosyltransferase inhibitors |
| 01/30/2003 | WO2003008396A1 Optically active oxazine derivative |
| 01/30/2003 | WO2003008392A1 4-(benzylidene-amino)-3-(methylsulfanyl)-4h-(1, 2, 4) triazin-5-one derivatives having a pde-iv inhibiting and tnf-antagonistic effect for the treatment of cardiac diseases and allergies |
| 01/30/2003 | WO2003008387A1 Compounds useful for treatment or prevention of disease mediated by alpha-2b-adrenoceptor |
| 01/30/2003 | WO2003008384A1 Substituted 2-thio-3, 5-dicyano-4-phenyl-6-aminopyridines and their use as adenosine receptor-selective ligands |
| 01/30/2003 | WO2003008380A1 Carboxylic acid derivatives |
| 01/30/2003 | WO2003008379A1 Azasugar compounds |
| 01/30/2003 | WO2003008374A1 Inhibitors of the ice/ced-3 family of cysteine proteases |
| 01/30/2003 | WO2003008371A1 Substituted 4-aminocyclohexanol derivatives |
| 01/30/2003 | WO2003008365A2 Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents |
| 01/30/2003 | WO2003007993A1 Combination of an aldosterone receptor antagonist and an hmg coa reductase inhibitor |
| 01/30/2003 | WO2003007992A1 Remedies for brain ischemic diseases |
| 01/30/2003 | WO2003007991A1 Pancreatic juice secretion regulators comprising lpa receptor controller |
| 01/30/2003 | WO2003007990A1 Myosin agonist |
| 01/30/2003 | WO2003007982A1 Sustained release hgf hydrogel preparations |